Its latest quarterly revenue reached 15.23M, representing a year-over-year increase of 8.84%, while its net profit experienced a year-over-year increase of 2.29%.
The current valuation score of Champions Oncology Inc is 9.20. Its current P/E ratio is -27.59, which is -3040.75% below the recent high of 811.43 and -859.34% above the recent low of -264.71.
No earnings forecast score is currently available for Champions Oncology Inc. The Biotechnology & Medical Research industry's average is 8.12. The average price target is 12.00, with a high of 12.00 and a low of 12.00.
The current price momentum score of Champions Oncology Inc is 3.12. Currently, the stock price is trading between the resistance level at 5.08 and the support level at 4.53, making it suitable for range-bound swing trading.
The latest institutional shareholding proportion is 47.97%, representing a quarter-over-quarter decrease of 7.89%.
The current risk assessment score of Champions Oncology Inc is 3.88. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.